Loading market dashboard
Omeros Corporation
OMERHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Omeros (OMER) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Omeros NASDAQ: OMER reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA.
Omeros Corporation (OMER) Q1 2026 Earnings Call Transcript
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include: First Quarter and Recent Highlights In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction of wholesaler distribution fees and chargebacks, were $9.9 million. Net income for the first quarter of.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the first quarter 2026 on Wednesday, May 13, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please click.
Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.
The consensus price target hints at a 222.8% upside potential for Omeros (OMER). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The Zacks Medical - Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. PAHC, BLFS, OMER and BWAY reflect the favorable fundamentals.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for YARTEMLEA®. The J-code for YARTEMLEA (J1289) simplifies and streamlines billing and reimbursement for patients covered by U.S. government programs (e.g., Medicare) and commercial payers. The J-code will become effective July 1, 2026. “For patients with TA-TMA, access to e.
Omeros Corporation (NASDAQ: OMER - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have given a buy recommendation and two have given a
The average of price targets set by Wall Street analysts indicates a potential upside of 266.7% in Omeros (OMER). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
JPMorgan Chase and Co. grew its position in Omeros Corporation (NASDAQ: OMER) by 1,201.1% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 416,153 shares of the biopharmaceutical company's stock after buying an additional 384,168 shares during the
Medtronic (NYSE: MDT - Get Free Report) and Omeros (NASDAQ: OMER - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends. Volatility and Risk Medtronic has a beta of 0.75, suggesting
Omeros Corporation maintains a Buy rating, driven by Yartemlea's FDA approval for TA-TMA and the Novo Nordisk zaltenibart deal. OMER's 2025 net loss narrowed to $(3.35m) due to a $237.6m gain on zaltenibart rights; cash position improved and debt reduced by 47%. Yartemlea, priced at $36k per vial, targets a potential $5.4bn TAM with first-mover advantage, but faces potential pricing and competitive risks as Soliris generics emerge.
Omeros Corporation (NASDAQ: OMER - Get Free Report) saw some unusual options trading activity on Wednesday. Stock traders purchased 7,487 call options on the company. This represents an increase of approximately 54% compared to the typical daily volume of 4,876 call options. Insider Activity In related news, CAO David J. Borges sold 30,000 shares of the
Omeros Corporation (OMER) Q4 2025 Earnings Call Transcript
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2025, which include: Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, or $0.54 per share, for the fourth quarter of 2024. For the year ended December 31, 2025, net loss was $3.4 million, or $0.05 per share, compared to a net loss of $1.
Shares of Omeros Corporation (NASDAQ: OMER - Get Free Report) crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $9.71 and traded as high as $10.06. Omeros shares last traded at $9.81, with a volume of 1,080,894 shares traded. Analyst Upgrades and Downgrades A number of
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the fourth quarter and year ended December 31, 2025, on Tuesday, March 31, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results. Conference Call Details and Webcast Link Instructions To access t.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, from 2:30pm - 4pm CET in Madrid, Spain. The session, titled “Advances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted Therapy,” will be co-chaired by Rafael Duarte, MD, PhD, Hospital Universitario Puerta de Hierro Majadahonda, and Mohamad Mohty, MD, PhD, Hôp.
Omeros Corporation (NASDAQ: OMER - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have given a buy recommendation and one has assigned
Senestech (NASDAQ: SNES - Get Free Report) and Omeros (NASDAQ: OMER - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability. Valuation and Earnings This table compares Senestech and Omeros"s
